J&J Scraps Late-Stage RSV Vaccine in R&D Overhaul, Dropping Out of Race with GSK, Pfizer

The healthcare giant’s pharmaceutical unit Janssen announced the end of work on the adult respiratory syncytial virus vaccine program and the discontinuation of a pivotal Phase III trial.